Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications – a review

Bogna Grygiel-Górniak

Abstract

Peroxisome proliferator-activated receptors are expressed in many tissues, including adipocytes, hepatocytes, muscles and endothelial cells; however, the affinity depends on the isoform of PPAR, and different distribution and expression profiles, which ultimately lead to different clinical outcomes. Because they play an important role in lipid and glucose homeostasis, they are called lipid and insulin sensors. Their actions are limited to specific tissue types and thus, reveal a characteristic influence on target cells. PPARα mainly influences fatty acid metabolism and its activation lowers lipid levels, while PPARγ is mostly involved in the regulation of the adipogenesis, energy balance, and lipid biosynthesis. PPARβ/δ participates in fatty acid oxidation, mostly in skeletal and cardiac muscles, but it also regulates blood glucose and cholesterol levels. Many natural and synthetic ligands influence the expression of these receptors. Synthetic ligands are widely used in the treatment of dyslipidemia (e.g. fibrates - PPARα activators) or in diabetes mellitus (e.g. thiazolidinediones - PPARγ agonists). New generation drugs - PPARα/γ dual agonists - reveal hypolipemic, hypotensive, antiatherogenic, anti-inflammatory and anticoagulant action while the overexpression of PPARβ/δ prevents the development of obesity and reduces lipid accumulation in cardiac cells, even during a high-fat diet. Precise data on the expression and function of natural PPAR agonists on glucose and lipid metabolism are still missing, mostly because the same ligand influences several receptors and a number of reports have provided conflicting results. To date, we know that PPARs have the capability to accommodate and bind a variety of natural and synthetic lipophilic acids, such as essential fatty acids, eicosanoids, phytanic acid and palmitoylethanolamide. A current understanding of the effects of PPARs, their molecular mechanisms and the role of these receptors in nutrition and therapeutic treatment are delineated in this paper.

Introduction

Peroxisome proliferator-activated receptors are ligand-activated transcription factors that regulate genes important in cell differentiation and various metabolic processes, especially lipid and glucose homeostasis. In molecular terms, PPARs represent a family of ligand-activated nuclear hormone receptors (NRs) belonging to the steroid receptor superfamily [1,2] (Figure 1). Examples of NRs include the receptors for thyroid hormones, retinoids, 1,25-dihydroxy-vitamin D3, steroid hormone receptors and a variety of other ligands. After interaction with the specific ligands, nuclear receptors are translocated to the nucleus, where they change their structure and regulate gene transcription [3-5].

PPAR structure and function

The three-dimensional structure of PPARs consists of a DNA binding domain in the N-terminus and a ligand binding domain (LBD) in the C-terminus. After interaction with agonists, PPARs are translocated to the nucleus and heterodimerize with another nuclear receptor - the retinoid X receptor (RXR) (Figure 2). The RXR forms a heterodimer with a number of other receptors (e.g., vitamin D or thyroid hormones). The specific DNA regions of target genes that bind with PPARs are termed peroxisome proliferator hormone response elements (PPREs) [1]. The PPREs are found in the promoters of PPAR responsive genes, such as the fatty acid-binding...
protein (aP2) [5]. In most cases, this process activates transcription of various genes involved in diverse physiological and pathophysiological processes.

The function of PPARs is modified by a number of co-activators and corepressors, the presence of which can either stimulate or inhibit receptor function, respectively [6]. Ligands that activate PPARγ-RXR cause an exchange of co-repressors for co-activators [7,8]. Human cells are characterized by a different availability of cofactors that depends on the type of cell and the association of specific cofactors to other genes [7,9,10].

Types of PPARs and their tissue expression

The family of peroxisome proliferation-activated receptors comprises three isoforms: PPARα, PPARβ/δ and PPARγ [1]. These three isotypes differ from each other in terms of their tissue distributions, ligand specificities and physiological roles. Each of them either activates or suppresses different genes with only partial overlap in activity (Figure 3) [5]. All isoforms participate in lipid homeostasis and glucose regulation (energy balance), and, until recently, their actions were thought to be limited to specific tissue types (Figure 4) [5,11]. PPARα is highly expressed in metabolically active tissues, such as liver, heart, skeletal muscle, intestinal mucosa and brown adipose tissue. This receptor is implicated in fatty acid metabolism and its activation lowers lipid levels [12-15].

PPARγ is expressed in white and brown adipose tissue, the large intestine and spleen. However, its expression is highest in adipocytes and it plays a key role in the regulation of adipogenesis, energy balance, and lipid biosynthesis [14,16-18]. This receptor also participates in lipoprotein metabolism and insulin sensitivity.

The least known isoform is PPARβ/δ, which has not been so intensely studied as PPARα and PPARγ. PPARβ/δ is expressed ubiquitously in virtually all tissues; however, it is particularly abundant in the liver, intestine, kidney, abdominal adipose tissue, and skeletal muscle, all of which are involved in lipid metabolism. It participates in fatty acid oxidation, mainly in skeletal and cardiac muscles, regulates blood cholesterol concentrations and glucose levels [1,13,19,20].

In conclusion, PPARα and PPARβ/δ mainly facilitate energy combustion, whereas PPARγ contributes to energy storage by enhancing adipogenesis [21].

PPAR ligands

Many natural and synthetic agonists of PPARs are used in the treatment of glucose and lipid disorders. PPARs perform different activities, mainly via endogenous ligands produced in the metabolic pathways of fatty acids; and therefore, they are called lipid sensors. PPAR agonists have different properties and specificities for individual PPAR receptors, different absorption/distribution profiles, and distinctive gene expression profiles, which ultimately lead to different clinical outcomes [1,5,17,22,23].

The characteristic feature of the PPAR ligand binding cavity is its size, which is 3–4 times larger than that of the other nuclear receptors. Thus, PPARs have the capability to accommodate and bind a variety of natural and synthetic lipophilic acids, such as essential fatty acids (EFA) (Figure 5). These acids act as PPAR agonists that transcript the genes involved in glucose and lipid
homeostasis [12,22,24]. They include docosahexaenoic acid and eicosapentaenoic acid used in the prevention and treatment of cardiovascular and metabolic diseases [25]. Not only EFA but also eicosanoids are natural ligands of PPARs – e.g. leukotriene B4 stimulates PPARα, and prostaglandin PGJ2 activates PPARγ [22]. However, both EFA and eicosanoids are required in relatively high concentrations (approximately 100 μM) for PPAR activation [24]. Also, synthetic ligands are widely used in clinical practice – for example, fibrates (PPARα ligands) are recommended in the dyslipidemic state (hypertriglyceridemia) and thiazolidinediones (PPARγ agonists) are used in the treatment of diabetes mellitus [26-29].

### Functional role of PPARα

As mentioned above, PPARα is expressed mainly in tissues with a high capacity for fatty acid oxidation, e.g. the liver, heart, and skeletal muscle. It also plays a role in glucose homeostasis and insulin resistance development (Figure 6) [29]. Natural or pharmacological ligands (fatty acids and fibrates, respectively) primarily control the expression of genes involved in lipid metabolism. If the concentration of fatty acids increases, PPARα is activated and uptakes oxidized forms of these acids [30,31]. Oxidation of fatty acids is mainly present in the liver and it prevents steatosis in the case of starvation/fasting. During the influx of fatty acids, transcription of PPARα-regulated genes is stimulated and the oxidation systems (microsomal omega-oxidation system, and mitochondrial and peroxisomal beta-oxidation) are activated (Figure 7) [21,32]. This activation and increased PPARα sensing in the liver result in increased energy burning and reduced fat storage. Conversely, ineffective PPARα sensing or decreased fatty acid oxidation causes a reduction in energy burning that results in hepatic steatosis and steatohepatitis (especially during overnight or prolonged fasting).

### Gene targets of PPAR α, β/δ, and γ

| PPARα | PPARβ/δ | PPARγ |
|-------|---------|-------|
| • β-oxidation pathway (acyl-CoA oxidase, thiolase) | • Genes involved in lipid uptake, metabolism and efflux (repressed by PPARα) | • Fatty acid-binding protein (aP2) |
| • Sterol 12-hydroxylase (CYP8B1) | • Fatty acid transport protein (FATP) | • Fatty acid transport protein (FATP) |
| • Fatty acid translocase (FAT/CD36) | • Lipoprotein lipase | • Fatty acid translocase (FAT/CD36) |
| • Apolipoprotein A-I and A-II |

Figure 3 PPARs and their gene targets.

### Tissue expression of PPAR α, β/δ, and γ

| PPARα | PPARβ/δ | PPARγ |
|-------|---------|-------|
| Main tissue expression: tissues exhibiting high carbolic rates of fatty acids (mainly liver and skeletal muscle) | Tissue expression: ubiquitous, however the biggest expression is in gastrointestinal tract (esophageous, liver, intestines) kidneys and skeletal muscle | Main tissue expression: adipose tissue (white and brown) |
| Other tissues: cardiomyocytes, kidney, intestinal mucosa, and brown adipose tissue | Other tissues: intestines, liver, kidneys, retina, immunologic system (bone marrow, lymphocytes, monocytes and macrophages), trace amounts in muscles |

Figure 4 Expression of PPARs in specific tissues.
The diminished effectiveness of oxidation systems is caused by genetic or toxic factors (including drug related ones), and metabolic disturbances. In animal models, inefficient PPARα sensing (characteristic for PPARα−/− mice) enables the oxidation of the influxed fatty acids and leads to severe hepatic steatosis development. Administration of PPARα agonists prevents these processes and even reverses hepatic fibrosis (in animal models) [34]. Thus, PPARα functions as a lipid sensor and it controls energy combustion. It also plays also a prominent role in the pathogenesis of fatty liver disease (FLD) and ligands of this receptor might be effective in the reduction of hepatic steatosis by increasing energy utilization [32,33].

**Natural agonists of PPARα**
The natural ligands of PPARα are omega-3 fatty acids. These acids contain three essential elements for optimal...
binding: a polar head group (a carboxylic group in the molecule of docosahexaenoic acid – DHA and eicosapentaenoic acid – EPA), a linker region (their long chains), and a hydrophobic tail [16]. Because omega-3 fatty acids are highly polyunsaturated, they readily undergo oxidation and stimulate PPARs. Sethi et al. proved that not only native EPA but also oxidized EPA modestly activates PPARα. Moreover, oxidized EPA, much more than native EPA, stimulates this receptor in endothelial cells. Therefore, it is suspected that oxidation of the omega-3 fatty acids converts them into a stronger PPARα agonist [30]. Similarly, oxidation of LDL transforms them into potent stimulators of PPARα in endothelial cells [31]. Thus, the possibility of lipid oxidation may be one of the first steps involved in the generation of efficient PPARα agonists.

In addition to PPAR activation, EPA and DHA have many beneficial health effects which are not characteristic for PPAR ligands. They reduce the risk of coronary heart disease, hypertension, primary heart attack, rheumatoid arthritis and play an important role in the development of attention-deficit/hyperactivity disorder [25]. These beneficial effects are not observed with other typical PPARs ligands; however, EPA and DHA do not show a number of PPAR effects, such as decreasing insulin resistance, that probably occur due to dissociation between n-3 polyunsaturated fatty acids and lipid metabolism in the hyperglycemic state [35].

Omega-3 fatty acids also reveal an anti-inflammatory effect that results from the inhibition of their own oxidation caused by activated NF-κB in a PPARα-dependent pathway [14,16]. In addition, PPARα mediates the anti-inflammatory actions of palmitoylethanolamide, the naturally occurring amide of palmitic acid and ethanolamine [15].

**Synthetic agonists of PPARα**

Synthetic PPARα ligands such as fibrates (e.g. clofibrate, fenofibrate, and bezafibrate) decrease the triglyceride-rich lipoproteins in serum through an increase in the gene expression involved in fatty acid-β-oxidation and a decrease in apolipoprotein C-III gene expression [26,29]. They are widely used in the pharmacological treatment of hypertriglyceridemia. After activation by fibrates, PPARα receptors connect with the 9-cis retinoic acid receptor and then bind to peroxisome proliferator response elements. Fibrates not only reveal a triglyceride-lowering effect, but also increase HDL cholesterol (partly by increasing apolipoprotein A-I and A-II gene expression). Their activity results in decreasing systemic availability of fatty acids and a lowering of fatty acid uptake in muscles. They also increase insulin sensitization and reduce plasma glucose levels [12,26,29]. In consequence, they may slow arteriosclerosis progression and reduce cardiovascular events [36]. However, two large-scale studies into fibrates (the FIELDstudy and the ACCORDlipid arm) in patients with diabetes did not show any reduction in fatal cardiovascular incidences or non-fatal myocardial infarction and stroke compared with simvastatin alone [37,38]. It must also be underlined that fibrate intake may cause an increase in serum creatinine levels (via a decrease in tubular secretion, reduced clearance and possibly increased production of creatinine) [39-41]. However, long-term studies have shown a slowing of the decline in renal function [37-39].

Active metabolites of fibrates, such as clofibric acid and fenofibric acid, are dual activators of PPARα and PPARγ, with about a 10-fold selectivity for PPARγ. The effect of bezafibrate, another compound from this group, is wider because it activates all 3 PPAR subtypes (α, γ and δ) at comparable doses to other fibrates [1,5]. Therefore, bezafibrate is considered a panagonist for all 3 PPAR isoforms with the potential to directly improve insulin sensitization via PPARγ activation.

**Functional role of PPARβ/δ**

PPARβ/δ (referred to also as PPARδ, PPARβ, hNUC1 or FAAR) plays a key role in lipid and cholesterol metabolism.
It is implicated in fatty acid oxidation, improving lipid profiles and reducing adiposity, which in consequence prevents obesity development [19,42]. In animals, PPARβ/δ serves as a regulator of fat consumption. PPARβ/δ-deficient mice challenged with a high-fat diet showed reduced energy uncoupling and were prone to obesity, whereas PPARβ/δ activation led to resistance to nutritionally (induced by high-fat diet) or genetically triggered obesity (in genetically modified mice) [19].

Decreased PPARβ/δ expression is also observed in cardiac muscle during the hyperglycemic state in diabetes mellitus [43,44]. Conversely, overexpression of this receptor in cardiac cells diminishes lipid accumulation in the presence of a high fat diet, and increases glucose metabolism. In consequence, the heart is protected against ischemia-reperfusion injury, suggesting that activation of this receptor might be useful in diabetic cardiomyopathy [45].

Also beneficial is PPARβ/δ activation in adipocytes and skeletal muscles that results in fatty acid oxidation and utilization (studies in vitro) [19]. Thus, PPARβ/δ might be considered a potential target in the treatment of obesity and obesity related disorders. This receptor is also a mediator of embryo implantation and cancer development [42,46]. Its high expression in the large intestine has been implicated in the development of colon cancer [11,47]. In this process, PPARβ/δ was stimulated by arachidonic acid, which resulted in the upregulation of cyclooxygenase (COX)-2 and the overproduction of prostaglandin (PG)E2 – an activator of colon cancer cells. Similarly, activation of PPARβ/δ also stimulated the cell line proliferation of human breast and prostate cancer [20].

**Agonists of PPARβ/δ**

Dual agonists of PPARβ/δ improve insulin sensitivity in both murine models and in humans. Thus, they might be considered a potential target in the treatment of obesity and obesity associated disorders. Only bezafibrate, a traditional PPARα agonist, seems to be a safe pan-agonist for all PPAR isotypes, but it has relatively low potency and low affinity for PPARβ/δ [48].

**Clinical and nutritional role of PPARy**

PPARγ has attracted significant scientific and clinical interest because of its role in macronutrient metabolism. It is a target of the synthetic insulin sensitzers – thiazolidinediones - used in the treatment of type 2 diabetes mellitus. This receptor is abundantly expressed in adipose tissue where it plays a central role in adipogenesis and appears to be primarily involved in the regulation of lipid metabolism. Because the PPARγ gene has separate promoters and 5’ exons, it results in three mRNAs: PPARγ1, PPARγ2, and PPARγ3. Proteins produced from PPARγ1 and PPARγ3 mRNAs are identical, whereas the product of PPARγ2 contains an additional NH₂-terminal region composed of 30 amino acids. All PPARγ isoforms play an important role in adipocyte differentiation and glucose metabolism; however, their expression is different. The PPARγ1 isoform is expressed in nearly all cells, while PPARγ2 is limited mainly to adipose tissue. Nevertheless, PPARγ2 is a more potent transcription activator [8].

Both forms of PPARγ1 and PPARγ2 are essential for the development of adipose tissue and the control of insulin sensitivity. However, PPARγ2 is the isoform regulated in response to nutrient intake and obesity [9,10]. The study of Medina-Gomez et al. based on an animal model proved that removing PPARγ2 from genetically obese POKO mice decreases the fat accumulation in adipocytes compared to normal obese mice on the same diet. This study showed that the PPARγ2 isoform prevents lipotoxicity in different mechanisms including promotion of adipose tissue expansion, the augmentation of lipid-buffering capacity in peripheral organs (liver, muscle, and beta cells of pancreas), and the proliferative response of β-cells to insulin resistance [18].

Adipose PPARγ protects non-adipose tissues against excessive lipid overload and maintains normal organ function (liver, skeletal muscle). Activated PPARγ in adipocytes guarantees a balanced and adequate secretion of adipocytokines (adiponectin and leptin) that are mediators of insulin action in peripheral tissues. In consequence, the insulin sensitivity of the whole body is maintained [49]. Apart from this adipogenetic activity, PPARγ is also important in lipid metabolism, and it regulates the genes participating in the release, transport, and storage of fatty acids such as lipoprotein lipase (LPL) and the fatty acid transporter CD36 [9,17,18]. PPARγ is the potent function modulator not only found in adipose tissue but also in endothelial cells and vascular smooth muscle cells. In endothelial cells it regulates targets relevant to inflammation and atherosclerosis [50].

Despite controlling lipid metabolism, PPARγ also participates in the regulation of cancer development. Their agonists inhibit or promote cancer growth depending on cellular conditions and the stimulated signaling pathway (anti-proliferative and apoptotic) [8,31]. They influence tumor-associated macrophages and tumor vasculature and significantly attenuate tumor progression [23]. These data suggested that PPARγ ligands may become new convenient therapeutic modifiers targeting simultaneously tumors and their microenvironment [51].

**Natural agonists of PPARγ**

The selective PPARγ modulators are often called SPARMs by analogy to selective estrogen receptor modulators
(SERMs). The distinct actions of SPARMs depend on the cellular context and on different receptor conformations, resulting in diverse gene interactions [52].

Selected fatty acids are considered natural modulators of PPARγ; however, their connection with the receptor does not always lead to PPAR activation and target gene transcription. Activation of PPARγ by natural ligands such as PUFAs (mainly docosahexaenoic acid and eicosapentaenoic acid) results in a functional response in the tumor cells. Many studies have provided evidence that DHA inhibits the tumor development through activation of PPARγ (e.g., the growth of human lung cancer cells) [53]. If DHA is delivered to breast cancer cells by albumin or by enriched LDL with n-3 PUFAs, it inhibits the proliferation of these cells and stimulates their apoptosis [54-56]. Syndecan-1 (the heparan sulfate proteoglycan) - the activating factor of apoptosis - participates in this process. After the stimulation of PPARγ by DHA, the transcriptional upregulation of the syndecan-1 target gene is present [56]. In animal studies long-chain mono-unsaturated fatty acids (LC-MUFAs) with chain lengths longer than 18 (i.e., C20:1 and C22:1 isomers combined) may ameliorate obesity-related metabolic dysfunction through increased expression of PPARγ and decreased inflammatory marker expression in white adipose tissue [57]. In in vitro studies, activation of PPARα and PPARβ/δ in human cell lines of breast cancer stimulated cell proliferation [58,59], whereas ligands for PPARγ inhibited this process [20].

Apart from polyunsaturated fatty acids, phytanic acid is also a natural PPARγ agonist in the human diet that reveals a similar activity to omega-3 PUFA and increases glucose uptake and insulin sensitivity; however, with less capacity to differentiate adipocytes [60].

**PPARγ pharmacological agonists**

PPARγ is a regulator of lipid and glucose metabolism and therefore its synthetic ligands such as glitazones – the derivatives of thiazolidinediones (e.g., troglitazone, rosiglitazone and pioglitazone) - improve insulin and glucose parameters and increase whole body insulin sensitivity. Therefore, they are called insulin-sensitizing medications used in the treatment of diabetes [61]. They indirectly increase insulin-stimulated glucose uptake in adipocytes, hepatocytes and skeletal muscle cells [62,63]. The effects of pharmacological PPARγ activation by thiazolidinediones have been attributed, at least in part, to decreased free fatty acid (FFA) levels and increased lipid storage in adipose tissue, in which it is most highly expressed. In consequence, lipotoxicity in the muscles and liver is reduced. PPARγ agonists also have the ability to redistribute fat from visceral to subcutaneous depots and increase adiponectin and reduce tissue necrosis factors [63,64]. Moreover, rosiglitazone and pioglitazone are used in the treatment of patients with type 2 diabetes because they decrease hepatic glucose production and prolong pancreatic β-cell function by preventing apoptosis of β-cells [62,63]. They reduce fasting plasma glucose and glycated hemoglobin A1c (pioglitazone 15–45 mg/day, rosiglitazone 2–6 mg/twice a day) [65-67]. However, the influence of both thiazolidinediones on cardiovascular outcomes in patients with diabetes mellitus is different. The positive effect of pioglitazone was demonstrated in a PROactive study revealing 16% reduced cardiovascular complications in the main secondary endpoint (a composite of all-cause-mortality, non-fatal myocardial infarction and stroke) compared with placebo treatment [68]. Conversely, rosiglitazone was associated with significant increases in myocardial infarction and death from cardiovascular causes after only relatively short-term exposure [69] and the European Medicines Agency withdrew approval of this medication in 2010 due to these cardiovascular safety concerns [64]. The differences between thiazolidinediones are probably caused by their diverse effects on lipid sub-fractions [63]. Pioglitazone increases HDL cholesterol and decreases triglycerides and fasting plasma free fatty acids (without any influence on total cholesterol and LDL cholesterol) [64,70,71]. Rosiglitazone significantly augments HDL levels [64,70,71], total cholesterol and the LDL fraction [71].

In diabetes mellitus, long-term activation of PPARγ by thiazolidinediones not only reduces glycaemia and insulinemia but also attenuates vascular dysfunction [72]. PPARγ is expressed in vessels, specifically in vascular smooth muscle cells and endothelium. Recent studies suggest that activators of PPARγ not only modify metabolic disturbances but also protect vascular function in diabetes [72]. Using an animal model, Bagi et al. proved that short-term treatment of type 2 diabetic mice with rosiglitazone augmented NO-mediated flow-dependent dilations of coronary arterioles by reducing vascular superoxide production via a favorable alteration of oxidant/antioxidant enzyme activities [73]. PPARγ agonists also lower blood pressure and decrease circulating PAI-1 and CRP levels in patients with diabetes [27,28].

Apart from these positive effects, activation of PPARγ by glitazones attenuates systemic inflammation [3,4] and reduces tumor growth and angiogenesis. PPARγ activation by agonist RS5444 may inhibit anaplastic thyroid cancer growth [74]. Only troglitazone revealed tumor-promoting and pro-angiogenic properties – it promoted hepatic carcinogenesis and liposarcomas, and thus this agonist was rejected from the treatment [72,75].

Despite many beneficial features of glitazones (metabolic and anti-atherosclerotic activity), they also exhibit side effects, such as weight gain, edema, bone fractures, heart failure and increased risk of myocardial infarctions, which have limited the use of these drugs in diabetic
patients with high lipid levels [76]. Fortunately, new selective PPAR\(\gamma\) modulators are currently in development (such as S26948 [77] and INT131 [78]) and these should stimulate glucose metabolic pathways and minimize the side effects of full PPAR-\(\gamma\) agonists.

**PPAR\(\alpha\)/\(\gamma\) dual agonists**

The synthesis of new drug generation - PPAR\(\alpha\)/\(\gamma\) dual agonists - connecting positive influences on both lipid and glucose metabolism has been recently developed as a response to the treatment challenge of co-existing type 2 diabetes mellitus with dyslipidemia. These double agonists not only have anti-diabetic capacity but also reduce atherosclerosis development. They also exhibit anti-inflammatory and anticoagulant action, improve endothelial function, decrease plasma free fatty acids and lower blood pressure revealing beneficial effects on the vasculature. However, recent studies show that PPAR\(\alpha\)/\(\gamma\) dual agonists, similar to glitazones, exhibit the same side effects; for example, weight gain and edema [48,79]. None of them may be safely used in clinical treatment because of the increased risk of bladder cancer and hyperplasia (ragaglitazar and naveglitazar) [80], renal dysfunction (tesaglitazar) [81] and increased cardiovascular risk (muraglitazar) [82]. A recent study (currently in phase III trials) of aleglitazar demonstrates that PPAR\(\alpha\)/\(\gamma\) dual agonists, similar to their close derivatives are being targeted as future drugs against metabolic diseases. Even though early preclinical data are very promising, it is necessary to evaluate the clinical properties of new PPAR agonists and their influence on patient health.

**Conclusions**

Considering the wide range of actions on glucose, lipid metabolism and cell proliferation/apoptosis, PPARs and their modulators are suggested for the treatment of metabolic disorders such as hyperglycemia, dyslipidemia and atherosclerosis. The prevention and treatment of both lipid and glucose profile disorders should consider the potency and affinity of selective PPARs and their potential cancerogenic influences. Therefore, natural compounds and their close derivatives are being targeted as future drugs against metabolic diseases. Even though early preclinical data are very promising, it is necessary to evaluate the clinical properties of new PPAR agonists and their influence on patient health.

**Competing interests**

The author declares that he has no competing interests.

**Acknowledgments**

This work was supported by the Polish National Science Centre (NSC) under the Grant No. N404 504 638.

Received: 8 October 2013 Accepted: 7 February 2014

**References**

1. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409–435.
2. Rohrer E, Gautier JC, Roberts R: Advances in understanding the regulation of apoptosis and mitosis by peroxisome proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol 2003, 21(1).
3. Rogge A, Lambert C, Josse R, Antheuier S, Spire C, Claude N, Guillouzo A: Comparative gene expression profiles induced by PPAR\(\alpha\) and PPAR\(\gamma\) agonists in human hepatocytes. PLoS One 2011, 6(4):e18816.
4. Rogge A, Spire C, Brun M, Claude N, Guillouzo A: Gene expression changes induced by PPAR\(\gamma\) gamma agonists in animal and human liver. PPAR Res 2010, 2010:325183.
5. Willson TM, Brown PJ, Stenbach DD, Henke BJ: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527–550.
6. Viswakarma N, Ji Y, Bai L, Vluggens A, Borensztajn J, Xu J, Reddy JK: Coactivators in PPAR-regulated gene expression. PPAR Res 2010, 2010:2050126.
7. Heikkinen S, Auwerx J, Argmann CA: PPARs in human and mouse physiology. Biochim Biophys Acta 2007, 1771(6):999–1013.
8. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006, 45(1):120–159.
9. Ren D, Collingwood TN, Rebar EJ, Wolfe AP, Camp HS: PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 2002, 16(1):27–32.
10. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and insulin of adipose tissue. J Biol Chem 1999, 272(32):20230–20235.
11. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regitnig W, Munoz DS, Kim JH, Shulman GI: n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes 2007, 56(4):1034–1041.
12. Deleire P, Furman C, Teissier E, Frucht J, Durie P, Saels B: Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEMS Lett 2000, 471(1):34–38.
13. Klenwer SA, Sundeth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Whali W, Willton TM, Lenhard JM, Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997, 94(9):4318–4323.
14. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 2005, 67(1):15–19.
15. Sheu SH, Kaya T, Waxman DJ, Vajda S: Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry (Mosc) 2005, 44(4):1193–1209.
16. Lehle M, Lazar MA: The many faces of PPARgamma. Cell 2005, 123(6):993–999.
17. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GSH, Lopez M, Seppanen-Laakso T, Ashcroft FM, Orešič M, Vidal-Puig A: PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet 2007, 3(4):e64.
18. Wang YX, Lee CH, Tieg S, Yu RT, Ham J, Kang H, Evans RW: Peroxisome proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113(2):159–170.
19. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CN: Activation of peroxisome
proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 2004, 64(9):3162–3170.

21. Rao MS, KashReddy P, Musunuri S, Okonkwo A: Prevention/ reversal of choline deficiency-induced steatohepatitis by a peroxisomeproliferator-activated receptor alpha ligand in rats. In Vivo 2002, 16(2):145–152.

22. Krey G, Brassard D, Horvat F, Kalkoven E, Porr M, Parker MG, Wohl W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11(6):779–791.

23. Margel A, Kourakis G, Theocharis S: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis 2003, 6(3):165–169.

24. Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep 2000, 2(4):327–335.

25. Bang JO, Dyberg J: Fish oil consumption and mortality from coronary heart disease. N Engl J Med 1985, 313(22):822–823.

26. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitasato N, Okumura T, Nagasaka S, Nakash S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001, 50(4):477–480.

27. Bakris GL, Dole JF, Porter LE, Huang C, Freed MI: Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000, 49(kuppl):11896.

28. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H: Peroxisome proliferator-activated receptor alpha ligand in rats. Mol Endocrinol 2003, 17(10):2343–2346.

29. Sethi S, Ziouzenkova O, Ni H, Wagner DO, Plutzky J, Mayadas TN: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100(6):1340–1346.

30. Davis TM, Ting JY, PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 2000, 11(4):137–142.

31. Michalik L, Desvergne B, Wahli W: Peroxisome proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004, 4(1):61–70.

32. Krey G, Brassard D, Horvat F, Kalkoven E, Porr M, Parker MG, Wohl W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997, 11(6):779–791.

33. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism 2001, 50(4):477–480.

34. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I: Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2005, 41(3):1122–1132.

35. Kriis-Elertson PM, Harris WS, Appel LJ: Omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Mol Cell Biol 2005, 25(6):2747–2757.

36. Diabetes Atherosclerosis Intervention Study investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised controlled trial. Lancet 2001, 357(9262):805–810.

37. Keech A, Elion N, Rose F, Achard JM, Fournier A: Fenofibrate increases creatinine clearance in patients with type 2 diabetes by increasing metabolic production of creatinine. Nephron 2000, 86(4):335–340.

38. Berger J, Leibowitz MD, Dobberw TB, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanien M, Venter J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Muller DE: Novel peroxisome proliferator-activated receptor gamma and PPARalpha ligands produce distinct biological effects. J Biol Chem 1999, 274(10):6718–6725.

39. Ngala RA, Stocker CJ, Roy AG, Hislop D, Wargent E, Bell R, Hassall DG, Harling JD, Billin AW, Wilson TM, Arch JR, Cawthorne MA: A new, highly selective marine peroxisome proliferator-activated receptor delta agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice. Diab Obes Metab 2011, 13(5):455–464.

40. N Engl J Med 2008, 362(1):2343–2346.

41. Dunlop DD, Wang S, Kjeldsen K, Simes RJ, Keech AC, Fenofibrate Intervention and Event Lowering in O’Connor RL, Whiting MJ, Glasziou PP, Simes RJ, Kesainen YA, Gebski VJ, ACCORD Study Group: Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010, 33(2):215–220.

42. Hottelant C, El Espiner N, Rose F, Achard JM, Fournier A: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2000, 86(4):335–340.

43. Davis TM, Ting JY, PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab 2000, 11(4):137–142.

44. Dunlop DD, Wang S, Kjeldsen K, Simes RJ, Keech AC, Fenofibrate Intervention and Event Lowering in O’Connor RL, Whiting MJ, Glasziou PP, Simes RJ, Kesainen YA, Gebski VJ, ACCORD Study Group: Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010, 33(2):215–220.

45. Hottelant C, El Espiner N, Rose F, Achard JM, Fournier A: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2000, 86(4):335–340.
60. Heim M, Johnson J, Boese F, Bendik I, Weber P, Hunziker W, Fluhmann B. Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J 2002, 16(7):718–720.

61. Elstner E, Mu¨ller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, DePaoli AM. Ligands for peroxisome proliferator-activated receptor y and retinoid acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998, 95(15):8864–8861.

62. Tan MH. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl 2000, 113:54–62.

63. Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.

64. Krishnaswami A, Ravi-Kumar S, Lewis JM. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.

65. Chang F, Jaber LA, Berlie HD, O Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007, 41(6):973–985.

66. Aronoff S, Rosenblatt B, Braithwaite S, Egan JW, Mathiesen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23(1):1605–1611.

67. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000, 43(3):278–284.

68. Dormandy J, Bhattacharya M, Van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009, 32(3):187–202.

69. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457–2471.

70. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004, 20(2):215–223.

71. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003, 63(13):1373–1403.

72. Caballero A, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O Connell MB. Thiazolidinediones in type 2 diabetes mellitus: a 2010 perspective. PAM J 2010, 14(3):64–72.

73. Chang F, Jaber LA, Berlie HD, O’Connell MB. Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother 2007, 41(6):973–985.

74. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Thiazolidinediones in type 2 diabetes: a 2010 overview of data from PROactive. Diabetologia 2011, 54(9):1771–1781.

75. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000, 43(3):278–284.

76. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Asou H, Shintaku P, Said JW, DePaoli AM. Ligands for peroxisome proliferator-activated receptor y and retinoid acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998, 95(15):8864–8861.

77. Tan MH. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl 2000, 113:54–62.

78. Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res 2008, 2008:520465.

79. Krishnaswami A, Ravi-Kumar S, Lewis JM. Thiazolidinediones: a 2010 perspective. Perm J 2010, 14(3):64–72.

80. Nissen SE, Wolski K. Topol 4: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356(24):2457–2471.

81. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004, 20(2):215–223.

82. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003, 63(13):1373–1403.

83. Caballero A, Saouaf R, Lim SC, Hanody O, Abou-Elenin K, O’Connor C, LoGerfo FW, Horton ES, Veves A. The effects of pioglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism 2003, 52(2):173–180.

84. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arteries of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004, 286(2):H742–H748.

85. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gurmz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res 2009, 69(4):1536–1544.

86. Tolman KG. The safety of thiazolidinediones. Expert Opin Drug Saf 2011, 10(3):419–428.

87. Rubenstrunk A, Hanf R, Hum DW, Frucht JC, Staelens B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007, 1771(8):1065–1081.

88. Camrona MC, Loucke K, Lefebre B, Picon A, Hennuyer N, Audron-Bouchez V, Fievet C, Torper G, Formstecker P, Renard P, Lefebre P, Dacquet C, Staelens B, Casteilla L, Pénicaud L. Consortium of the French Ministry of Research and Technology: S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antithromogenic effects. Diabetes 2007, 56(11):2797–2808.

89. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complicat 2011, 25(3):151–158.

90. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004, 5(7):419–429.